{"id":"mianserin","rwe":[{"pmid":"41654948","year":"2026","title":"Storage stability of hospital-prepared mianserin suppositories: evaluation of residual active ingredient content and bacteriological contamination under different storage conditions.","finding":"","journal":"Journal of pharmaceutical health care and sciences","studyType":"Clinical Study"},{"pmid":"41519169","year":"2026","title":"Comparative acceptability of first-line antidepressants among older adults using filled prescription sequences: A nationwide cohort study.","finding":"","journal":"Journal of affective disorders","studyType":"Clinical Study"},{"pmid":"41496334","year":"2026","title":"Contribution of the serotonergic system to myopia and the therapeutic effects of atropine and pirenzepine.","finding":"","journal":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","studyType":"Clinical Study"},{"pmid":"41431689","year":"2025","title":"Analgesic Efficacy and Tolerability of Amitriptyline versus Mianserin in Chronic Low Back Pain: A Randomised, Double-Blind, Controlled Pilot Trial.","finding":"","journal":"Journal of pain research","studyType":"Clinical Study"},{"pmid":"41238422","year":"2026","title":"Validation in Drosophila of the in silico predicted clomipramine as repurposable for SOD1-ALS.","finding":"","journal":"Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics","studyType":"Clinical Study"}],"tags":[{"label":"mianserin","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Histamine H1 receptor","category":"target"},{"label":"HRH1","category":"gene"},{"label":"HTR2C","category":"gene"},{"label":"ADRA2C","category":"gene"},{"label":"N06AX03","category":"atc"},{"label":"Active","category":"status"},{"label":"Major depressive disorder","category":"indication"},{"label":"Adrenergic Agents","category":"pharmacology"},{"label":"Adrenergic Antagonists","category":"pharmacology"},{"label":"Adrenergic alpha-Antagonists","category":"pharmacology"},{"label":"Antidepressive Agents","category":"pharmacology"},{"label":"Antidepressive Agents, Second-Generation","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Histamine Agents","category":"pharmacology"},{"label":"Histamine Antagonists","category":"pharmacology"},{"label":"Histamine H1 Antagonists","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Psychotropic Drugs","category":"pharmacology"},{"label":"Serotonin Agents","category":"pharmacology"},{"label":"Serotonin Antagonists","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":293.858,"date":"","count":170,"signal":"Coma","source":"DrugCentral FAERS","actionTaken":"Reported 170 times (LLR=294)"},{"llr":173.87,"date":"","count":184,"signal":"Somnolence","source":"DrugCentral FAERS","actionTaken":"Reported 184 times (LLR=174)"},{"llr":169.605,"date":"","count":89,"signal":"Hepatocellular injury","source":"DrugCentral FAERS","actionTaken":"Reported 89 times (LLR=170)"},{"llr":168.054,"date":"","count":32,"signal":"Camptocormia","source":"DrugCentral FAERS","actionTaken":"Reported 32 times (LLR=168)"},{"llr":152.995,"date":"","count":39,"signal":"Pleurothotonus","source":"DrugCentral FAERS","actionTaken":"Reported 39 times (LLR=153)"},{"llr":151.307,"date":"","count":86,"signal":"Cholestasis","source":"DrugCentral FAERS","actionTaken":"Reported 86 times (LLR=151)"},{"llr":141.9,"date":"","count":59,"signal":"Poisoning deliberate","source":"DrugCentral FAERS","actionTaken":"Reported 59 times (LLR=142)"},{"llr":140.325,"date":"","count":78,"signal":"Agranulocytosis","source":"DrugCentral FAERS","actionTaken":"Reported 78 times (LLR=140)"},{"llr":130.422,"date":"","count":130,"signal":"Hyponatraemia","source":"DrugCentral FAERS","actionTaken":"Reported 130 times (LLR=130)"},{"llr":126.671,"date":"","count":224,"signal":"Fall","source":"DrugCentral FAERS","actionTaken":"Reported 224 times (LLR=127)"},{"llr":123.363,"date":"","count":194,"signal":"Drug interaction","source":"DrugCentral FAERS","actionTaken":"Reported 194 times (LLR=123)"},{"llr":117.287,"date":"","count":190,"signal":"Toxicity to various agents","source":"DrugCentral FAERS","actionTaken":"Reported 190 times (LLR=117)"},{"llr":110.508,"date":"","count":26,"signal":"Cerebral artery thrombosis","source":"DrugCentral FAERS","actionTaken":"Reported 26 times (LLR=111)"},{"llr":98.116,"date":"","count":24,"signal":"Brain scan abnormal","source":"DrugCentral FAERS","actionTaken":"Reported 24 times (LLR=98)"},{"llr":95.993,"date":"","count":63,"signal":"Altered state of consciousness","source":"DrugCentral FAERS","actionTaken":"Reported 63 times (LLR=96)"}],"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=MIANSERIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:17:34.339672+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:17:39.771955+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MIANSERIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:17:40.109344+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL544428/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:17:40.870366+00:00"}},"allNames":"(+/-)-mianserin","offLabel":[],"synonyms":["mianserin hydrochloride","mianserin","mianserine","(+/-)-Mianserin","mianserine hydrochloride","mianserin HCl","mianserine HCl"],"timeline":[{"date":"1976-01-01","type":"positive","source":"DrugCentral","milestone":"YEAR INTRODUCED approval"}],"approvals":[{"date":"1976-01-01","orphan":false,"company":"","regulator":"YEAR INTRODUCED"}],"brandName":"(+/-)-Mianserin","ecosystem":[{"indication":"Major depressive disorder","otherDrugs":[{"name":"brexpiprazole","slug":"brexpiprazole","company":"Otsuka Pharm Co Ltd"},{"name":"bupropion","slug":"bupropion","company":"Glaxosmithkline"},{"name":"citalopram","slug":"citalopram","company":"Forest Labs"},{"name":"desvenlafaxine","slug":"desvenlafaxine","company":"Wyeth Pharms Inc"}],"globalPrevalence":280000000}],"mechanism":{"target":"Histamine H1 receptor","targets":[{"gene":"HRH1","source":"DrugCentral","target":"Histamine H1 receptor","protein":"Histamine H1 receptor"},{"gene":"HTR2C","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2C","protein":"5-hydroxytryptamine receptor 2C"},{"gene":"ADRA2C","source":"DrugCentral","target":"Alpha-2C adrenergic receptor","protein":"Alpha-2C adrenergic receptor"},{"gene":"ADRA2A","source":"DrugCentral","target":"Alpha-2A adrenergic receptor","protein":"Alpha-2A adrenergic receptor"},{"gene":"HTR2A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2A","protein":"5-hydroxytryptamine receptor 2A"},{"gene":"HTR2B","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2B","protein":"5-hydroxytryptamine receptor 2B"},{"gene":"HTR1F","source":"DrugCentral","target":"5-hydroxytryptamine receptor 1F","protein":"5-hydroxytryptamine receptor 1F"},{"gene":"ADRA2B","source":"DrugCentral","target":"Alpha-2B adrenergic receptor","protein":"Alpha-2B adrenergic receptor"},{"gene":"HTR1B","source":"DrugCentral","target":"5-hydroxytryptamine receptor 1B","protein":"5-hydroxytryptamine receptor 1B"},{"gene":"ADRA1D","source":"DrugCentral","target":"Alpha-1D adrenergic receptor","protein":"Alpha-1D adrenergic receptor"}],"modality":"Small Molecule","drugClass":"mianserin","explanation":"","oneSentence":"","technicalDetail":"Mianserin acts as a selective antagonist at the histamine H1 receptor, which is involved in the regulation of mood, appetite, and sleep-wake cycles. This action is thought to contribute to its antidepressant effects by increasing the levels of certain neurotransmitters, such as serotonin and norepinephrine, in the brain."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1796","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=MIANSERIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=MIANSERIN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:07:51.599410","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:17:42.602633+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"tryptophan","drugSlug":"tryptophan","fdaApproval":"","relationship":"same-class"},{"drugName":"nomifensine","drugSlug":"nomifensine","fdaApproval":"","relationship":"same-class"},{"drugName":"trazodone","drugSlug":"trazodone","fdaApproval":"1981-12-24","patentExpiry":"Mar 27, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"nefazodone","drugSlug":"nefazodone","fdaApproval":"1994-12-22","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"viloxazine","drugSlug":"viloxazine","fdaApproval":"2021-04-02","patentExpiry":"Sep 4, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"mirtazapine","drugSlug":"mirtazapine","fdaApproval":"1996-06-14","genericCount":19,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"bupropion","drugSlug":"bupropion","fdaApproval":"1985-12-30","patentExpiry":"Jun 27, 2026","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"venlafaxine","drugSlug":"venlafaxine","fdaApproval":"1993-12-28","genericCount":41,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"milnacipran","drugSlug":"milnacipran","fdaApproval":"2009-01-14","patentExpiry":"Sep 19, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"duloxetine","drugSlug":"duloxetine","fdaApproval":"2004-08-03","patentExpiry":"Apr 13, 2037","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"desvenlafaxine","drugSlug":"desvenlafaxine","fdaApproval":"2008-02-29","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"vilazodone","drugSlug":"vilazodone","fdaApproval":"2011-01-21","genericCount":5,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"vortioxetine","drugSlug":"vortioxetine","fdaApproval":"2013-09-30","patentExpiry":"Sep 21, 2032","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"esketamine","drugSlug":"esketamine","fdaApproval":"2019-05-03","patentExpiry":"Sep 10, 2035","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"levomilnacipran","drugSlug":"levomilnacipran","fdaApproval":"2013-07-25","patentExpiry":"May 23, 2032","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"brexanolone","drugSlug":"brexanolone","fdaApproval":"2019-03-19","patentExpiry":"Nov 27, 2033","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"mianserin","indications":{"approved":[{"name":"Major depressive disorder","source":"DrugCentral","snomedId":370143000,"regulator":"FDA","usPrevalence":21000000,"globalPrevalence":280000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"tryptophan","brandName":"tryptophan","genericName":"tryptophan","approvalYear":"","relationship":"same-class"},{"drugId":"nomifensine","brandName":"nomifensine","genericName":"nomifensine","approvalYear":"","relationship":"same-class"},{"drugId":"trazodone","brandName":"trazodone","genericName":"trazodone","approvalYear":"1981","relationship":"same-class"},{"drugId":"nefazodone","brandName":"nefazodone","genericName":"nefazodone","approvalYear":"1994","relationship":"same-class"},{"drugId":"viloxazine","brandName":"viloxazine","genericName":"viloxazine","approvalYear":"2021","relationship":"same-class"},{"drugId":"mirtazapine","brandName":"mirtazapine","genericName":"mirtazapine","approvalYear":"1996","relationship":"same-class"},{"drugId":"bupropion","brandName":"bupropion","genericName":"bupropion","approvalYear":"1985","relationship":"same-class"},{"drugId":"venlafaxine","brandName":"venlafaxine","genericName":"venlafaxine","approvalYear":"1993","relationship":"same-class"},{"drugId":"milnacipran","brandName":"milnacipran","genericName":"milnacipran","approvalYear":"2009","relationship":"same-class"},{"drugId":"duloxetine","brandName":"duloxetine","genericName":"duloxetine","approvalYear":"2004","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05599126","phase":"PHASE4","title":"A Study of Mianserin in Combination With SSRIs in Depression With Sleep Problems","status":"RECRUITING","sponsor":"Zhenghui YI","startDate":"2024-07-01","conditions":["Depression"],"enrollment":300,"completionDate":"2025-12-30"},{"nctId":"NCT05952713","phase":"","title":"Comparative Responses to 15 Different Antidepressants in Major Depressive Disorder","status":"COMPLETED","sponsor":"Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital","startDate":"2022-10-01","conditions":["Major Depressive Disorder"],"enrollment":73336,"completionDate":"2023-07-01"},{"nctId":"NCT02761161","phase":"PHASE4","title":"Treatment of Sleep Disturbances in Trauma-affected Refugees","status":"COMPLETED","sponsor":"Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital","startDate":"2016-03","conditions":["Post Traumatic Stress Disorder","Depression"],"enrollment":241,"completionDate":"2019-06-01"},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":["Dementia","Depression","Schizophrenia","Psychosomatic Disorders","Anxiety Disorders"],"enrollment":407,"completionDate":"2017-06-28"},{"nctId":"NCT01305707","phase":"PHASE4","title":"Continuation Electroconvulsive Therapy (C-ECT) for Relapse Prevention in Major Depression","status":"TERMINATED","sponsor":"Hospital Universitari de Bellvitge","startDate":"2009-07","conditions":["Depression"],"enrollment":104,"completionDate":"2014-07"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"MMSL":"18113","NDDF":"004006","UNII":"250PJI13LM","CHEBI":"CHEBI:51137","VANDF":"4027429","INN_ID":"2543","RXNORM":"203127","UMLSCUI":"C0025912","chemblId":"CHEMBL544428","ChEMBL_ID":"CHEMBL6437","KEGG_DRUG":"D01358","DRUGBANK_ID":"DB06148","PUBCHEM_CID":"4184","SNOMEDCT_US":"387565003","IUPHAR_LIGAND_ID":"135","SECONDARY_CAS_RN":"21535-47-7","MESH_DESCRIPTOR_UI":"D008803"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"9.6 hours","clearance":"21.9 mL/min/kg","bioavailability":"22%","fractionUnbound":"0.05%","volumeOfDistribution":"13.75 L/kg"},"publicationCount":2071,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"N06AX03","allCodes":["N06AX03"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Feb 7","pmid":"41654948","title":"Storage stability of hospital-prepared mianserin suppositories: evaluation of residual active ingredient content and bacteriological contamination under different storage conditions.","journal":"Journal of pharmaceutical health care and sciences"},{"date":"2026 May 1","pmid":"41519169","title":"Comparative acceptability of first-line antidepressants among older adults using filled prescription sequences: A nationwide cohort study.","journal":"Journal of affective disorders"},{"date":"2026 Jan","pmid":"41496334","title":"Contribution of the serotonergic system to myopia and the therapeutic effects of atropine and pirenzepine.","journal":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie"},{"date":"2025","pmid":"41431689","title":"Analgesic Efficacy and Tolerability of Amitriptyline versus Mianserin in Chronic Low Back Pain: A Randomised, Double-Blind, Controlled Pilot Trial.","journal":"Journal of pain research"},{"date":"2026 Jan","pmid":"41238422","title":"Validation in Drosophila of the in silico predicted clomipramine as repurposable for SOD1-ALS.","journal":"Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"withdrawn","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"OTHER","regulator":"YEAR INTRODUCED","status":"approved","approval_date":"1976-01-01T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:17:42.602633+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}